What are the safety, efficacy, and long-term effects of GLP-1 (Glucagon-Like Peptide-1) injections, such as liraglutide (Victoza), for weight loss and Hormone Replacement Therapy (HRT) for perimenopause and postmenopause symptoms in adult patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 27, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

GLP-1 Receptor Agonists for Weight Loss and HRT for Perimenopause/Postmenopause

GLP-1 Receptor Agonists for Weight Loss

Primary Recommendation for Weight Loss

For weight loss in adults with obesity (BMI ≥30) or overweight (BMI ≥27 with comorbidities), tirzepatide 15mg weekly achieves superior weight loss (20.9% at 72 weeks) compared to semaglutide 2.4mg weekly (14.9% at 68 weeks), making it the first-line choice when maximum weight loss is the priority. 1

However, semaglutide 2.4mg weekly should be prioritized for patients with established cardiovascular disease due to its proven 20% reduction in cardiovascular death, nonfatal MI, or nonfatal stroke (HR 0.80). 1

Efficacy in Perimenopausal and Postmenopausal Women

  • Postmenopausal women achieve comparable weight loss to premenopausal women with semaglutide 1mg, with 5.8% weight loss after 4 months despite having higher baseline weight and fat mass. 2
  • Postmenopausal women using hormone replacement therapy (HRT) concurrently with semaglutide achieve significantly greater weight loss (16% at 12 months) compared to those not on HRT (12% at 12 months), even after adjusting for confounders. 3
  • Women on HRT are more likely to achieve ≥10% total body weight loss at 12 months compared to those not on HRT. 3

Mechanism of Action and Additional Benefits

  • GLP-1 receptor agonists work through multiple mechanisms: suppressing appetite via hypothalamic signaling, delaying gastric emptying, increasing glucose-dependent insulin release, decreasing glucagon secretion, and promoting pancreatic β-cell growth. 1
  • Tirzepatide's dual GIP/GLP-1 receptor activation provides enhanced metabolic benefits including superior triglyceride reduction, greater waist circumference reduction, and better fasting glucose control compared to semaglutide. 1

Cardiovascular and Metabolic Benefits Beyond Weight Loss

  • Semaglutide 2.4mg reduces the composite incidence of cardiovascular death, nonfatal MI, or nonfatal stroke by 20% (HR 0.80) in patients with cardiovascular disease and BMI ≥27, even without diabetes. 1
  • GLP-1 receptor agonists reduce albuminuria and slow eGFR decline, with significant reduction in composite kidney disease outcomes (macroalbuminuria, eGFR decline, progression to kidney failure). 1
  • Both semaglutide and tirzepatide improve blood pressure, lipid profiles, and insulin sensitivity, potentially requiring antihypertensive medication adjustments as weight decreases. 1
  • Semaglutide shows promise for NASH resolution, achieving 59% resolution at 0.4mg/day versus 17% with placebo, allowing simultaneous treatment of obesity, cardiovascular disease, and liver disease. 1

Safety Profile and Adverse Effects

  • Gastrointestinal effects (nausea, vomiting, diarrhea, constipation) are the most common adverse effects, occurring in 47-84% of patients versus 13-63% with placebo, but are typically mild-to-moderate and transient. 4
  • Treatment discontinuation rates are 34 more per 1000 patients with semaglutide compared to placebo, primarily due to gastrointestinal effects. 1
  • Serious adverse events including pancreatitis and gallbladder disease (cholelithiasis, cholecystitis) occur but are rare, with causality not definitively established. 1
  • Both medications are absolutely contraindicated in patients with personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN2) based on animal studies. 1

Long-Term Effects and Maintenance

  • Sudden discontinuation of GLP-1 receptor agonists results in regain of one-half to two-thirds of lost weight within 1 year, making lifelong treatment necessary for sustained benefits. 1
  • After cessation of semaglutide, significant weight regain occurs (11.6% of lost weight regained after 52 weeks), highlighting the need for long-term use. 1
  • Real-world discontinuation rates are high (20-50%) within the first year, often due to gastrointestinal side effects or cost, especially when not covered by insurance. 5

Practical Prescribing Approach

  • Semaglutide 2.4mg titration schedule: start at 0.25mg weekly for 4 weeks, increase to 0.5mg for 4 weeks, then 1.0mg for 4 weeks, then 1.7mg for 4 weeks, reaching maintenance dose of 2.4mg weekly after 16 weeks. 1
  • Tirzepatide titration schedule: start at 5mg weekly, increase every 4 weeks based on tolerance to maximum dose of 15mg weekly. 1
  • Slow titration is essential to minimize gastrointestinal side effects, which are dose-dependent and more frequent with rapid escalation. 1
  • Physical activity, specifically resistance training, should be part of the recommended approach to preserve lean body mass alongside GLP-1 RAs, as liraglutide alone without lifestyle co-interventions results in more lean body mass loss than placebo. 6

Monitoring Requirements

  • Assess patients every 4 weeks during titration for gastrointestinal tolerance, weight loss progress, and blood pressure. 1
  • After reaching maintenance dose, monitor at least every 3 months for weight stability, cardiovascular risk factors, medication adherence, and adverse effects. 1
  • Evaluate treatment efficacy at 12-16 weeks on maximum tolerated therapeutic dose; discontinue if weight loss is <5% after 3 months. 1

Hormone Replacement Therapy (HRT) for Perimenopause and Postmenopause

Primary Recommendation for Symptom Management

For perimenopausal and postmenopausal women seeking relief from menopausal symptoms (hot flashes, night sweats, vaginal dryness), HRT should be used at the lowest effective dose for the shortest possible time, with decisions based on shared decision-making that considers individual risk factors and personal preferences. 6

Risk-Benefit Profile

  • For 10,000 women ages 50-79 taking estrogen and progestin for 1 year, there would be 7 additional CHD events, 8 more strokes, 8 more pulmonary emboli, and 8 more invasive breast cancers, but also 6 fewer cases of colorectal cancer and 5 fewer hip fractures. 6
  • The absolute increase in risk from HRT is modest, and some women, depending on their risk characteristics and personal preferences, might decide that the benefits outweigh the potential harms. 6

Timing and Duration Considerations

  • Some risks (venous thromboembolism, CHD, stroke) occur within the first 1-2 years of therapy, whereas other risks (breast cancer) appear to increase with longer-term HRT use. 6
  • Women who decide to take HRT for relief of menopausal symptoms should use the lowest effective dose for the shortest possible time. 6

Important Limitations of Evidence

  • Most evidence on HRT comes from observational studies that did not differentiate among effects of specific hormone preparations, with only two large randomized controlled trials of daily conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA). 6
  • Until data indicate that other HRT regimens have a favorable balance of benefits to harms, a cautious approach would be to avoid using HRT routinely for the specific purpose of preventing chronic disease in women. 6
  • Evidence is insufficient to determine whether unopposed estrogen benefits outweigh harms for women who have had a hysterectomy. 6

Shared Decision-Making Approach

  • Clinicians should develop a shared decision-making approach to preventing chronic diseases in perimenopausal and postmenopausal women, considering individual risk factors and preferences in selecting effective interventions for reducing risks for fracture, heart disease, and cancer. 6
  • Women should be informed about the risks and benefits of HRT, including the timing of different risks, to make informed decisions about initiating or continuing therapy. 6

Alternative Strategies

  • Clinicians should discuss with patients other effective strategies for preventing osteoporosis and fractures, including screening for postmenopausal osteoporosis, hypertension, lipid disorders, counseling to prevent tobacco use, promoting healthy diet and physical activity, and screening for breast and colorectal cancer. 6
  • Evidence is inconclusive to determine whether phytoestrogens (isoflavones found in soy products) are effective for reducing risk of osteoporosis or cardiovascular disease. 6

Synergistic Effects: GLP-1 RAs and HRT in Postmenopausal Women

  • Postmenopausal women using HRT concurrently with semaglutide achieve significantly greater weight loss (16% at 12 months) compared to those not on HRT (12% at 12 months), suggesting a synergistic effect. 3
  • Both groups experience improvement in cardiometabolic risk markers (glucose, blood pressure, lipids) at 12 months, regardless of HRT use. 3
  • The association between HRT use and improved weight loss response remains significant after adjusting for potential confounders including age, race, BMI, and comorbidities. 3

Patient Education Resources

For GLP-1 Receptor Agonists:

  1. American Diabetes Association (diabetes.org) - Comprehensive information on GLP-1 receptor agonists for weight management and diabetes
  2. American Heart Association (heart.org) - Cardiovascular benefits of GLP-1 receptor agonists
  3. Obesity Medicine Association (obesitymedicine.org) - Patient resources on pharmacotherapy for obesity
  4. FDA Drug Safety Communications - Official safety information on semaglutide (Wegovy) and tirzepatide (Zepbound)

For Hormone Replacement Therapy:

  1. North American Menopause Society (menopause.org) - Evidence-based information on menopause management and HRT
  2. American College of Obstetricians and Gynecologists (acog.org) - Patient education materials on menopause and hormone therapy
  3. National Institutes of Health Women's Health Initiative - Results from landmark HRT trials
  4. International Menopause Society (imsociety.org) - Global perspectives on menopause management

For Combined Approach:

  1. Endocrine Society (endocrine.org) - Information on metabolic health in menopause and obesity management
  2. American Association of Clinical Endocrinologists (aace.com) - Guidelines on obesity and menopause management

References

1
Guideline

Pharmacological Management of Obesity

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

6
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

Is Ozempic (semaglutide) effective for treating postmenopausal symptoms?
Does Vitamin K with Glucagon-like peptide-1 (GLP-1) analogs help with weight loss?
What is the term for an error caused by an anaesthetist (anesthesiologist) placing two different medications with the same shape and colour on a drug preparation shelf?
Is the skinny fit GLP-1 (Glucagon-like peptide-1) oral supplement, containing chicory inulin, turmeric, berberine, and probiotic blend, safe and effective for weight loss?
What are the potential effects of the ResM GLP-1 Postbiotic supplement on the general health and weight loss of a patient with potential underlying conditions, such as Impaired renal function, considering its high doses of Vitamin B12 and Chromium?
What is the best course of treatment for a patient with a history of sinus infections, currently experiencing facial pain, congestion, and a runny nose, who has previously been prescribed Cephalexin (Keflex) (Cephalexin)?
What are the causes of hyperprolactinemia?
What is the recommended treatment for a patient with mononucleosis?
What alternative treatment options are available for a patient with chronic obstructive pulmonary disease (COPD) or asthma who has not responded to Advair (fluticasone and salmeterol) and Breyna (likely a misspelling of a medication, possibly referring to a bronchodilator or other respiratory medication)?
What is the appropriate management for a patient with mononucleosis presenting with left abdominal pain, suspected splenomegaly, and risk of splenic rupture?
Should a 32-month-old child with speech delay and autism spectrum disorder (ASD) exhibiting injurious behavior be referred to a psychiatrist?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question